DK1663161T3 - Estradiol-progesteron-formulering med langsom afgivelse - Google Patents

Estradiol-progesteron-formulering med langsom afgivelse Download PDF

Info

Publication number
DK1663161T3
DK1663161T3 DK04736545.7T DK04736545T DK1663161T3 DK 1663161 T3 DK1663161 T3 DK 1663161T3 DK 04736545 T DK04736545 T DK 04736545T DK 1663161 T3 DK1663161 T3 DK 1663161T3
Authority
DK
Denmark
Prior art keywords
estradiol
formulation
microspheres
progesterone
approx
Prior art date
Application number
DK04736545.7T
Other languages
English (en)
Inventor
John Claude Savoir
Uribe Juan Angeles
Original Assignee
Skendi Finance Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1663161(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Skendi Finance Ltd filed Critical Skendi Finance Ltd
Application granted granted Critical
Publication of DK1663161T3 publication Critical patent/DK1663161T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (14)

1. Formulering, som er egnet til administration til et hunpattedyr og omfatter ca. 5 til ca. 15 mg 17-p-estradiol blandet med cholesterol i et ca. 1:1 molært forhold og ca. 200 til ca. 500 mg progesteron; hvor vægtforholdet mellem 17-p-estradiol og progesteron er ca. 1:40; 17-p-estradiol består af en hemikrystallinsk form, som erca. 50-60% amorf og ca. 40-50% krystallinsk; og EDR af formuleringen er ca. 20% eller mindre.
2. Formulering ifølge krav 1, hvor 17-p-estradiol består af en hemikrystallinsk form, som er ca. 55% amorf og ca. 45% krystallinsk.
3. Formulering ifølge krav 1 eller krav 2, hvor EDR er ca. 6% eller mindre.
4. Formulering ifølge et hvilket som helst af kravene 1 til 3, hvor estradiol/cholesterol-blandingen og progesteron er formuleret som mikrosfærer med en diameter på ca. 35 til ca. 75 μιτι.
5. Formulering, som omfatter en præventionseffektiv og hormonerstatningseffektiv mængde 17-p-estradiol og progesteron i et vægtforhold på ca. 1:40, og hvor 17-p-estradiol er sammensat i separate partikler i blanding med cholesterol.
6. Formulering ifølge krav 5, hvor vægtforholdet 17-p-estradiol:progesteron er 9:400.
7. Formulering ifølge krav 5, hvor 17-p-estradiol og cholesterol er sammensat i et 1:1 molært forhold til mikrosfærer, og progesteron er separat sammensat til separate mikrosfærer.
8. Formulering ifølge krav 5, hvor mikrosfærerne har en diameter på mellem ca. 25 μηι og ca. 105 prn.
9. Formulering ifølge et hvilket som helst af kravene 1 til 8, som er egnet til parenteral administration.
10. Formulering ifølge krav 9, som er egnet til intramuskulær injektion.
11. Formulering ifølge et hvilket som helst af kravene 1 til 10 til anvendelse til prævention i et hunpattedyr i de reproduktive år.
12. Formulering ifølge et hvilket som helst af kravene 1 til 10 til anvendelse til hormonerstatningsterapi i et hunpattedyr i de første fem år af menopausen.
13. Kit, som omfatter (1) en steril pakning omfattende en enhedsdosis afen formulering ifølge krav 1 i form af mikrosfærer i steril pulverform og (2) en steril pakning omfattende en vandig bærer til suspendering af mikrosfærerne til parenteral administration.
14. Kit ifølge krav 13, som desuden omfatter et middel til parenteral administration af formuleringen.
DK04736545.7T 2003-06-13 2004-06-10 Estradiol-progesteron-formulering med langsom afgivelse DK1663161T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47793903P 2003-06-13 2003-06-13
PCT/IB2004/001930 WO2004110408A2 (en) 2003-06-13 2004-06-10 Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol

Publications (1)

Publication Number Publication Date
DK1663161T3 true DK1663161T3 (da) 2015-04-27

Family

ID=33551788

Family Applications (3)

Application Number Title Priority Date Filing Date
DK04736545.7T DK1663161T3 (da) 2003-06-13 2004-06-10 Estradiol-progesteron-formulering med langsom afgivelse
DK07008942T DK1820494T3 (da) 2003-06-13 2004-06-10 Mikropartikler bestående af estradiol og cholesterol
DK07008938.8T DK1844765T3 (da) 2003-06-13 2004-06-10 Estradiol-progesteron-formulering med langsom afgivelse

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK07008942T DK1820494T3 (da) 2003-06-13 2004-06-10 Mikropartikler bestående af estradiol og cholesterol
DK07008938.8T DK1844765T3 (da) 2003-06-13 2004-06-10 Estradiol-progesteron-formulering med langsom afgivelse

Country Status (23)

Country Link
US (2) US7589082B2 (da)
EP (3) EP1663161B1 (da)
JP (2) JP4956185B2 (da)
CN (2) CN101816662B (da)
AT (1) ATE454885T1 (da)
AU (1) AU2004246870B2 (da)
BR (1) BRPI0411335A (da)
CA (2) CA2849228C (da)
CY (1) CY1109967T1 (da)
DE (1) DE602004025156D1 (da)
DK (3) DK1663161T3 (da)
EA (3) EA012783B1 (da)
ES (3) ES2537551T3 (da)
HU (1) HUE025147T2 (da)
IL (2) IL172466A (da)
MX (1) MX2008014654A (da)
NO (1) NO341540B1 (da)
OA (1) OA13307A (da)
PL (3) PL1844765T3 (da)
PT (3) PT1844765E (da)
SI (3) SI1844765T1 (da)
TW (1) TWI336623B (da)
WO (1) WO2004110408A2 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663161B1 (en) 2003-06-13 2015-01-14 Skendi Finance, Ltd. Slow release estradiol-progesterone formulation
US20110104289A1 (en) * 2008-04-14 2011-05-05 Posi Visionary Solutions Llp Method and pharmaceutical composition for obtaining the plasmatic progesterone levels required for different therapeutic indications
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
EP2701744A4 (en) * 2011-03-23 2014-08-20 Pop Test Cortisol Llc COMBINATION THERAPY
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2016018993A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
ITUB20153652A1 (it) * 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
EP3436023A4 (en) * 2016-04-01 2019-10-16 TherapeuticsMD, Inc. Pharmaceutical steroid hormone composition
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3272732B1 (de) 2016-07-19 2019-09-18 Evonik Degussa GmbH Verfahren zur alkoxycarbonylierung ethylenisch ungesättigter verbindungen mit monophosphinliganden
PL3886816T3 (pl) * 2018-11-29 2024-03-04 Insigna Inc. Benzoesan estradiolu jako środek sterylizujący
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
EP3954364A1 (en) * 2020-08-14 2022-02-16 Chemo Research, S.L. New modified release oral contraceptive composition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800038A (en) * 1972-04-21 1974-03-26 Biolog Concepts Inc Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
GB1367608A (en) * 1973-03-09 1974-09-18 Biolog Concepts Inc Oral pharmaceutical dosage form
US4218255A (en) * 1976-08-30 1980-08-19 University Of Dayton Porous ceramic carriers for controlled release of proteins, polypeptide hormones, and other substances within human and/or other mamillian species and method
US4180560A (en) * 1976-10-26 1979-12-25 Syntex Corporation Inert core implant pellet
JPS5799562A (en) 1980-12-12 1982-06-21 Nippon Shinyaku Co Ltd Preparation of microcrystal
US5023092A (en) * 1988-06-16 1991-06-11 Ici Americas Inc. Mannitol having gamma sorbitol polymorph
IT1230566B (it) 1988-10-17 1991-10-28 Vectorpharma Int Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
IE62665B1 (en) * 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
DE4130173A1 (de) 1991-09-11 1993-03-18 Bayer Ag Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters
SE9301171D0 (sv) * 1993-04-07 1993-04-07 Ab Astra Pharmaceutical composition containing lipophilic drugs
TW404844B (en) 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
FR2747042B1 (fr) * 1996-04-05 1998-06-05 Besins Iscovesco Lab Medicament a base de progesterone et d'oestradiol
US5762956A (en) * 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
EP0888790A1 (en) 1997-07-04 1999-01-07 PowderJect Research Limited Drug particle delivery device
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
CN1290507C (zh) * 2000-12-14 2006-12-20 奥索-麦克尼尔药品公司 甾类激素产品及其制备方法
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
EP1663161B1 (en) 2003-06-13 2015-01-14 Skendi Finance, Ltd. Slow release estradiol-progesterone formulation

Also Published As

Publication number Publication date
SI1844765T1 (sl) 2015-05-29
MX2008014654A (es) 2009-03-09
CA2849228C (en) 2016-09-20
AU2004246870B2 (en) 2009-07-23
HK1109586A1 (en) 2008-06-13
EA018356B1 (ru) 2013-07-30
US20050025827A1 (en) 2005-02-03
EA201201221A1 (ru) 2014-02-28
ES2537551T3 (es) 2015-06-09
NO20060200L (no) 2006-01-13
CY1109967T1 (el) 2014-09-10
JP4956185B2 (ja) 2012-06-20
PL1663161T3 (pl) 2015-08-31
PT1820494E (pt) 2010-04-14
AU2004246870A1 (en) 2004-12-23
NO341540B1 (no) 2017-12-04
EP1663161A2 (en) 2006-06-07
WO2004110408A3 (en) 2005-04-14
EA012783B1 (ru) 2009-12-30
EA200600029A1 (ru) 2006-08-25
IL210851A (en) 2016-05-31
EA026709B1 (ru) 2017-05-31
TW200514560A (en) 2005-05-01
DK1844765T3 (da) 2015-04-27
CN101816662B (zh) 2015-01-28
PT1844765E (pt) 2015-05-20
EP1820494A3 (en) 2007-09-19
CA2528545C (en) 2014-08-12
WO2004110408A2 (en) 2004-12-23
ES2537563T3 (es) 2015-06-09
EP1663161B1 (en) 2015-01-14
EP1820494A2 (en) 2007-08-22
TWI336623B (en) 2011-02-01
PT1663161E (pt) 2015-05-13
PL1820494T3 (pl) 2010-07-30
SI1663161T1 (sl) 2015-05-29
EP1820494B1 (en) 2010-01-13
US8163722B2 (en) 2012-04-24
HK1147426A1 (en) 2011-08-12
EA200900451A1 (ru) 2009-12-30
HK1106717A1 (en) 2008-03-20
CN100594907C (zh) 2010-03-24
EP1844765A1 (en) 2007-10-17
DK1820494T3 (da) 2010-05-25
DE602004025156D1 (de) 2010-03-04
JP2011157386A (ja) 2011-08-18
IL172466A0 (en) 2006-04-10
EP1844765B1 (en) 2015-01-21
PL1844765T3 (pl) 2015-06-30
CA2528545A1 (en) 2004-12-23
OA13307A (en) 2007-04-13
CA2849228A1 (en) 2004-12-23
HK1097735A1 (zh) 2007-07-06
US20090081303A1 (en) 2009-03-26
CN1835737A (zh) 2006-09-20
US7589082B2 (en) 2009-09-15
HUE025147T2 (hu) 2016-03-29
CN101816662A (zh) 2010-09-01
BRPI0411335A (pt) 2006-07-25
IL172466A (en) 2011-11-30
SI1820494T1 (sl) 2010-08-31
JP2006527263A (ja) 2006-11-30
ES2340422T3 (es) 2010-06-02
IL210851A0 (en) 2011-04-28
ATE454885T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
US8163722B2 (en) Pharmaceutical formulation for contraception and hormone-replacement therapy
HK1106717B (en) Microparticles consisting of estradiol and cholesterol
HK1109586B (en) Slow release estradiol-progesterone formulation
MXPA05013507A (es) Formulacion de liberacion lenta de estradiol-progesterona paraanticoncepcion y terapia de reemplazo hormonal
HK1097735B (en) Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol
HK1147426B (en) Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol
Segal Contraceptives for the Twenty-First Century
KR100481459B1 (ko) 에스트로겐,프로게스틴또는이의혼합물의경피투여용조성물